Ozempic ( semaglutide ) is a popular GLP-1 medication for type 2 diabetes, but it isn't the only option
Significantly raises levels of NAD+, a molecule cells need for energy, by blocking an enzyme called NNMT
Regardless of the injuries, plaintiffs universally allege that the manufacturers either failed to properly test GLP-1 medications before they were put on the market, failed to provide patients and their doctors with adequate warnings about the health risks, or failed to do both
doi: 10.1134/S0006297919080017 143
Novo reported that, in a late-stage study, a next-generation obesity drug called CagriSema led patients to lose 20% of their weight at 68 weeks when looking at all participants less than the companys own projection of about 25% weight loss
EBioMedicine 21 , 2128 (2017)